» Articles » PMID: 27774097

PPAR in Bacterial Infections: A Friend or Foe?

Overview
Journal PPAR Res
Publisher Wiley
Date 2016 Oct 25
PMID 27774097
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Peroxisome proliferator-activated receptor (PPAR) is now recognized as an important modulator of leukocyte inflammatory responses and function. Its immunoregulatory function has been studied in a variety of contexts, including bacterial infections of the lungs and central nervous system, sepsis, and conditions such as chronic granulomatous disease. Although it is generally believed that PPAR activation is beneficial for the host during bacterial infections via its anti-inflammatory and antibacterial properties, PPAR agonists have also been shown to dampen the host immune response and in some cases exacerbate infection by promoting leukocyte apoptosis and interfering with leukocyte migration and infiltration. In this review we discuss the role of PPAR and its activation during bacterial infections, with focus on the potential of PPAR agonists and perhaps antagonists as novel therapeutic modalities. We conclude that adjustment in the dosage and timing of PPAR agonist administration, based on the competence of host antimicrobial defenses and the extent of inflammatory response and tissue injury, is critical for achieving the essential balance between pro- and anti-inflammatory effects on the immune system.

Citing Articles

Unveiling the glycolysis in sepsis: Integrated bioinformatics and machine learning analysis identifies crucial roles for IER3, DSC2, and PPARG in disease pathogenesis.

Cui D, Yu T Medicine (Baltimore). 2024; 103(39):e39867.

PMID: 39331858 PMC: 11441936. DOI: 10.1097/MD.0000000000039867.


Gene Co-Expression Network Analysis Reveals the Hub Genes and Key Pathways Associated with Resistance to Enteritidis Colonization in Chicken.

Wang Q, Thiam M, Sanchez A, Wang Z, Zhang J, Li Q Int J Mol Sci. 2023; 24(5).

PMID: 36902251 PMC: 10003191. DOI: 10.3390/ijms24054824.


The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia.

Ferreira B, Ramirez-Moral I, Otto N, Salomao R, de Vos A, van der Poll T Clin Exp Immunol. 2022; 207(3):370-377.

PMID: 35553637 PMC: 9113127. DOI: 10.1093/cei/uxab036.


Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia.

Ramirez-Moral I, Ferreira B, de Vos A, van der Poll T Respir Res. 2021; 22(1):230.

PMID: 34412637 PMC: 8375046. DOI: 10.1186/s12931-021-01823-8.


Nuclear Receptors in Asthma: Empowering Classical Molecules Against a Contemporary Ailment.

Tiwari D, Gupta P Front Immunol. 2021; 11:594433.

PMID: 33574813 PMC: 7870687. DOI: 10.3389/fimmu.2020.594433.


References
1.
Kelly D, Campbell J, King T, Grant G, Jansson E, Coutts A . Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2003; 5(1):104-12. DOI: 10.1038/ni1018. View

2.
Li Y, Zhang J, Schopfer F, Martynowski D, Garcia-Barrio M, Kovach A . Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol. 2008; 15(8):865-7. PMC: 2538624. DOI: 10.1038/nsmb.1447. View

3.
Migliavacca M, Assanelli A, Ferrua F, Cicalese M, Biffi A, Frittoli M . Pioglitazone as a novel therapeutic approach in chronic granulomatous disease. J Allergy Clin Immunol. 2016; 137(6):1913-1915.e2. PMC: 4889778. DOI: 10.1016/j.jaci.2016.01.033. View

4.
Soller M, Tautenhahn A, Brune B, Zacharowski K, John S, Link H . Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis. J Leukoc Biol. 2005; 79(1):235-43. DOI: 10.1189/jlb.0205058. View

5.
Fajas L, Fruchart J, Auwerx J . PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 1998; 438(1-2):55-60. DOI: 10.1016/s0014-5793(98)01273-3. View